Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors

NCT05429762 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
56
Enrollment
INDUSTRY
Sponsor class

Stopped Tusamitamab ravtansine clinical development program is discontinued as CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival. The decision is not related to any safety concern.

Conditions

Interventions

Sponsor

Sanofi